May 8, 2024Clinical Gastroenterology and Hepatology22 citationsOpen Access
Ver artículo completoOzanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
The pivotal phase 3 True North (TN) study demonstrated the efficacy and safety of ozanimod in patients with moderately to severely active ulcerative colitis. This analysis assessed ozanimod during TN and the ongoing open-label extension (OLE) in patients with active disease who were naive to advanced therapies (ATs).